GlassScriptPhysician profile
Camysha H Wright
NPI 1497959092
$38,266.94
in general payments reported to CMS, 2019-2025
21 companies · $20K in 2025
The $20K reported for 2025 was more than what 98% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,779 · 2020: $168 · 2021: $549 · 2022: $581 · 2023: $633 · 2024: $14K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Honoraria: $7,700 · Travel and Lodging: $3,392 · Food and Beverage: $2,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,187.50 |
| Honoraria | $7,700.00 |
| Travel and Lodging | $3,392.32 |
| Food and Beverage | $2,909.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $24,119.24 | 2019-2025 | Latera, Scopis Ent, Clarifix Cryotherapy Device |
| Alk-Abello, INC | $10,293.51 | 2019-2025 | Odactra, Grastek, Ragwitek |
| Aerin Medical INC. | $1,568.90 | 2019-2023 | |
| Optinose US, INC. | $488.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $399.04 | 2022-2025 | Nucala |
| Genzyme Corporation | $318.42 | 2023-2025 | |
| Acclarent, INC | $220.84 | 2019-2022 | |
| Neurent Medical Limited | $170.35 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Intersect Ent, INC. | $143.35 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $98.15 | 2024-2025 | Dupixent |
| Smith+Nephew, INC. | $83.08 | 2019-2024 | |
| Phadia US INC. | $79.84 | 2022-2025 | Immunocap |
| Integra Lifesciences Corporation | $69.27 | 2023 | Codman Isocool Aht, Integra, Microfrance |
| Aroa Biosurgery Incorporated | $45.65 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $39.16 | 2025 | Neffy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.69 | 2019-2021 | |
| Resmed Corp | $32.25 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $17.24 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.19 | 2025 | Xhance |
| Novo Nordisk INC | $14.88 | 2020 | |
| Medtronic, INC. | $13.22 | 2023 | Sinuva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camysha Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.